Literature DB >> 2213119

Low dose rate radiotherapy for transplantable gliosarcoma in the rat brain.

J H Kim1, A A Alfieri, M Rosenblum, S Bravo, S H Kim.   

Abstract

Interstitial brachytherapy with low energy radionuclides is becoming widely used in conjunction with external beam radiotherapy in the treatment of primary malignant gliomas of the brain. Few radiobiological studies have been carried out with low dose rate brachytherapy for brain tumors. Since we have recently developed a non-invasive low dose rate radiotherapy model for the treatment of transplantable 9L gliosarcoma growing in the rat brain, we carried out a series of radiobiological studies to determine the dose rate effect on the tumor and normal brain tissue. Using TCD50 (the radiation dose to control 50% tumor control) as the endpoints, we obtained the results indicating that the tumor control rate was highly dependent on the dose rate and the total dose delivered to the tumor. The TCD50 of dose rates ranging from 100 cGy/min, 120 cGy/hr, and 40 cGy/hr were 25 Gy, 80 Gy, and 100 Gy, respectively. The normal tissue effects were most pronounced with high dose rate irradiation (100 cGy/min). The LD50 for high dose rate irradiation to the whole brain was 29 Gy. In contrast, the majority of animals treated with low dose rate radio-therapy behaved quite normal up to a year follow-up. The late histopathological changes of the irradiated brain usually consisted of vascular and white matter necrosis, although the extent of such changes showed a considerable individual variation within the long-term survivors.

Entities:  

Mesh:

Year:  1990        PMID: 2213119     DOI: 10.1007/bf00167063

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  10 in total

1.  Tumor and normal tissue response to irradiation in vivo: variation with decreasing dose rates.

Authors:  K K Fu; T L Phillips; L J Kane; V Smith
Journal:  Radiology       Date:  1975-03       Impact factor: 11.105

2.  The effect of continuous or fractionated irradiation on a murine sarcoma.

Authors:  R P Hill; R S Bush
Journal:  Br J Radiol       Date:  1973-03       Impact factor: 3.039

3.  Physical optimization of afterloading techniques.

Authors:  L L Anderson
Journal:  Strahlentherapie       Date:  1985-05

4.  Evidence for an unconventional radiosensitivity of rat 9L subcutaneous tumors.

Authors:  C A Wallen; S M Michaelson; K T Wheeler
Journal:  Radiat Res       Date:  1980-12       Impact factor: 2.841

5.  Pathologic findings in canine brain irradiated with fractionated fast neutrons or photons.

Authors:  B C Zook; E W Bradley; G W Casarett; C C Rogers
Journal:  Radiat Res       Date:  1980-12       Impact factor: 2.841

6.  Late changes in the architecture of blood vessels of the rat brain after irradiation.

Authors:  H S Reinhold; J W Hopewell
Journal:  Br J Radiol       Date:  1980-07       Impact factor: 3.039

Review 7.  Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources.

Authors:  P H Gutin; S A Leibel; W M Wara; A Choucair; V A Levin; T L Philips; P Silver; V Da Silva; M S Edwards; R L Davis
Journal:  J Neurosurg       Date:  1987-12       Impact factor: 5.115

8.  Iodine 125 source in interstitial tumor therapy. Clinical and biological considerations.

Authors:  J H Kim; B Hilaris
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1975-01

9.  Computed tomography analysis of the canine brain: effects of hemibrain X irradiation.

Authors:  J R Fike; C E Cann; R L Davis; J K Borcich; T L Phillips; L B Russell
Journal:  Radiat Res       Date:  1984-08       Impact factor: 2.841

10.  Radiation therapy of brain tumors.

Authors:  G E Sheline
Journal:  Cancer       Date:  1977-02       Impact factor: 6.860

  10 in total
  1 in total

1.  Preferential radiosensitization of 9L glioma cells transduced with HSV-tk gene by acyclovir.

Authors:  S H Kim; J H Kim; A Kolozsvary; S L Brown; S O Freytag
Journal:  J Neurooncol       Date:  1997-07       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.